SINGLE TRIALS WITH SIZE, POWERFUL STATISTICS OR CORROBATING ENDPOINTS MAY BE CONSIDERED AS SUPPORT FOR NDAs, FDA EXPLAINS IN EFFICACY EVIDENCE GUIDANCE

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".